Genomic Valley Biotech Sales Analyzed

Genomic Valley Biotech is currently facing a major problem. Their sales have dropped dramatically – a whopping 77% – and their profits have fallen even further. This means they made very little money this quarter, just Rs 0.05 crore, compared to Rs 0.22 crore last time.

Key Points

• Significant sales decline: 77.27% reduction to Rs 0.05 crore.
• Net profit plummeted: 93.75% drop to Rs 0.01 crore.
• Major revenue decrease: Sales decreased dramatically from Rs 0.22 crore.
• Profit margin severely impacted: OPM fell from 72.73% to 20.00%.
• Cost of goods and profit plummeted: PBDT and PBT decreased by 94%.
• Net profit loss substantial: Rs 0.01 crore compared to Rs 0.16 crore.

Detailed Results

Let’s break down the numbers. During the quarter that just ended (December 2025), the company only earned Rs 0.05 crore in sales. This is a huge drop from the previous quarter’s sales of Rs 0.22 crore – that’s almost a 77% difference. It’s important to note this was a significant decrease.

The company’s profit, called the “PBDT,” was also very low – just Rs 0.01 crore. This is a 94% drop from the previous quarter’s PBDT of Rs 0.16 crore. Similarly, the overall profit, called the “PBT,” only amounted to Rs 0.01 crore, reflecting a 94% decline.

Finally, the bottom line – the net profit – was only Rs 0.01 crore. This represents a staggering 94% decrease compared to the previous quarter’s profit of Rs 0.16 crore. These figures highlight a serious financial challenge for Genomic Valley Biotech.

Understanding these financial trends is crucial for guiding strategic decisions and ensuring long-term stability.